Jeanny B. Aragon-Ching, MD of the Inova Schar Cancer Institute has co-authored a groundbreaking bladder cancer research paper just published in the New England Journal of Medicine.
The large phase III clinical study showed that the addition of immunotherapy with Avelumab (Bavencio) increased the duration of overall survival by almost 50% in patients when given after chemotherapy in patients with locally advanced bladder cancer.
This practice-changing study showed how the addition of immunotherapy can have a dramatic impact on the lives of patients with certain cancers.
Three-part series in The Lancet examines cardiovascular risk before, during and after pregnancy as a…
In general, minimally invasive surgery refers to procedures performed using small incisions with the aid…
A national TODAY feature highlights the remarkable recovery of Bensten Schone, a McLean teenager who…
Leesburg, VA – Inova Loudoun Hospital Mobile Health Services will be providing countywide blood pressure…
Christina Baselga, MD is a primary care physician at Inova 360° Concierge Medicine. A board-certified…
Inova Schar Heart and Vascular is continuing to build upon its legacy of innovation in…